Append Medical
Append Medical has raised $4.35 million as part of an extended series A Round. Investors include participants from the first tranche of the A round as well as new investors, Shoni Health Ventures and ALIVE Israel HealthTech Fund. The funding announced today will be used to support the company's first-in-human trials of Appligator.
Append's Appligator is in development to be a next generation, left atrial appendage (LAA) Elimination System designed to completely close the LAA without metal implants or sealings, eliminate leaking, and as a result help reduce the risk of stroke for Atrial Fibrillation (AF) patients, a major clinical issue and a rapidly growing multi-billion dollar market.
